863,867 Shares in Artivion, Inc. $AORT Purchased by Summit Partners Public Asset Management LLC

Summit Partners Public Asset Management LLC acquired a new position in Artivion, Inc. (NYSE:AORT) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 863,867 shares of the company’s stock, valued at approximately $39,401,000.

Other institutional investors also recently made changes to their positions in the company. Fred Alger Management LLC lifted its holdings in shares of Artivion by 4.2% in the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after purchasing an additional 55,322 shares during the last quarter. Squarepoint Ops LLC raised its stake in Artivion by 309.3% during the 4th quarter. Squarepoint Ops LLC now owns 29,134 shares of the company’s stock valued at $1,329,000 after acquiring an additional 22,016 shares in the last quarter. Mariner LLC acquired a new position in shares of Artivion during the 4th quarter valued at $1,836,000. Entropy Technologies LP increased its position in shares of Artivion by 6.0% during the 4th quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock valued at $251,000 after purchasing an additional 310 shares during the period. Finally, Barclays PLC increased its position in shares of Artivion by 20.3% during the 4th quarter. Barclays PLC now owns 65,703 shares of the company’s stock valued at $2,997,000 after purchasing an additional 11,087 shares during the period. 86.37% of the stock is owned by institutional investors.

Insider Activity at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the transaction, the senior vice president directly owned 60,259 shares in the company, valued at approximately $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Artivion Trading Up 1.6%

Artivion stock opened at $21.41 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86. The business’s 50-day simple moving average is $28.41 and its 200-day simple moving average is $36.62. The firm has a market capitalization of $1.04 billion, a PE ratio of 89.23 and a beta of 1.26. Artivion, Inc. has a 52 week low of $19.16 and a 52 week high of $48.25.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on AORT shares. Canaccord Genuity Group restated a “buy” rating and issued a $36.00 target price on shares of Artivion in a report on Tuesday. Needham & Company LLC reduced their price objective on Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Weiss Ratings cut Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 8th. Finally, Citizens Jmp reduced their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.17.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.